Literature DB >> 3531309

A single nighttime dose of ranitidine 300 mg versus ranitidine 150 mg twice daily in the acute treatment of duodenal ulcer: a European multicenter trial.

B Simon, G Bianchi Porro, M Cremer, G Dobrilla, U Haglund, S L Dunn, K Summers.   

Abstract

Six hundred and five patients with endoscopically diagnosed duodenal ulcer were randomly allocated to treatment with ranitidine 300 mg at night or ranitidine 150 mg twice daily in a prospective double-blind multicenter trial conducted in nine European countries. Endoscopy at 4 weeks showed complete ulcer healing in 246 of 301 patients (82%) treated with ranitidine 150 mg b.i.d. and 230 of 304 patients (76%) treated with ranitidine 300 mg at night. Cumulative healing rates at 8 weeks were 95 and 94% respectively. Both treatment regimens were equally effective at rapidly reducing the incidence of ulcer-related symptoms. Adverse events were few and consistent with those reported in previous studies with ranitidine 150 mg twice daily. The results of this trial indicate that a single nighttime dose of ranitidine is an effective and safe alternative to the twice daily regimen in the acute treatment of duodenal ulcer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3531309     DOI: 10.1097/00004836-198606002-00007

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

Review 1.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 2.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

3.  Comparative study of mifentidine and ranitidine in the short-term treatment of duodenal ulcer.

Authors:  F Sabbatini; M Lazzaroni; M Petrillo; G Piai; G Mazzacca; G Bianchi Porro
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.